Panel-based TMB was not associated with PFS
cancer, cancers
CANCER, CANCERS, PEDIATRIC CANCER
We sought to determine the value of TMB as a predictive biomarker of response to ICI in pediatric cancers. TMB measured by the F1 CGP assay ranged from 0 to 18.4 mutations (mut) per Mb in 51 pre-treatment samples (median 2.6 mut per Mb; Extended Data Fig. While acknowledging the heterogeneity of cancer types in our cohort, we investigated whether recurrently altered genes were associated with PFS; we included short variants, insertion/deletions, rearrangements and copy number alterations. We found 25 genes that were altered in >10% of samples. Reflective of previous reports in pediatric and adult cancers, most recurrently altered genes included the chromatin remodeling gene, 